Findcure Biosciences (zhongshan) Co., Ltd.
Clinical trials sponsored by Findcure Biosciences (zhongshan) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New tracer could sharpen prostate cancer detection Results expected Oct 2026 (estimated)
- New drug cocktail aims to tackle Hard-to-Treat cancers Results expected Dec 2026 (estimated)
- New radioactive drug targets Hard-to-Treat cancers in early trial Results expected Dec 2026 (estimated)
- New radioactive drug targets Hard-to-Treat prostate cancer Results expected May 2027 (estimated)
-
New radioactive drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…
Early phase 1 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a combination of two drugs—FC084CSA and tislelizumab—in people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the safest dose and see if the combo can control tumor growth. Only 33 participa…
Phase 1/2 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new radioactive drug called 177Lu-FC516 in 13 men with advanced prostate cancer that has stopped responding to standard treatments. The drug is given every 6 weeks for up to 4 cycles. The main goals are to find the safest dose and check for side eff…
Early phase 1 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New tracer could sharpen prostate cancer detection
Diagnosis Recruiting nowThis early study tests a new radioactive tracer called 68Ga-FC516 in 10 healthy adults and people with prostate cancer. The goal is to see if it is safe and how well it finds tumors on PET/CT scans compared to existing tracers. The results will help improve prostate cancer diagno…
Early phase 1 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC